Issue Date: January 22, 2018
Vaccitech raises $27 million for the flu
Oxford University spin-off company Vaccitech has raised $27.1 million in series A funding to advance its universal flu vaccine and cancer vaccine programs. The flu vaccine, based on proteins conserved across all influenza A strains, is currently in a Phase IIb trial with over 800 people. Programs for four other infectious diseases are in various stages of development, and a Phase II trial for a prostate cancer vaccine will begin this year. Investors include GV (formerly Google Ventures), Sequoia China, Oxford Sciences Innovation, and Neptune Ventures.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society